IMMUNOHISTOCHEMICAL EXPRESSION OF P16 IN LOW GRADE UROTHELIAL CARCINOMA

Muhammad Umer Chaudry; Farhan Akhtar; Nighat Jamal; Hamza Mansur; Nozaif Sarwar; Yusra Saleem

doi:10.51253/pafmj.v71i3.6075

Authors

Muhammad Umer Chaudry Pakistan Naval Ship, Shifa Hospital, Islamabad Pakistan
Farhan Akhtar ak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Nighat Jamal Pakistan Naval Ship, Shifa Hospital, Islamabad Pakistan
Hamza Mansur Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Nozaif Sarwar Pakistan Naval Ship, Shifa Hospital, Islamabad Pakistan
Yusra Saleem Pakistan Naval Ship, Shifa Hospital, Islamabad Pakistan

DOI:

https://doi.org/10.51253/pafmj.v71i3.6075

Keywords:

Bladder cancer, Immunohistochemistry, Low grade P16 expression, Urothelial carcinoma

Abstract

Objective: To determine the frequency of Immunohistochemical expression of P16 in low grade urothelial carcinoma patients.

Study Design: Cross sectional study.

Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, from May 2018 to Jul 2019.

Methodology: A total of 120 formalin-fixed and paraffin embedded blocks from patients having low grade urothelial carcinomawere included in the study and were stainedimmunohistochemically with P16 antibody. Expression of P16 was noted by two independent pathologists and nuclear stain of strong intensity was taken as positive.

Results: There were 91 (76%) males and 29 (24%) females with age range from 18-85 years (mean 67.19 ± 11.5 years) female to male ratio was 1:3. P16 stain was positive in (70.8%) and negative in 37 (31%) of low gradeurothelial carcinoma cases.

Conclusion: The p-16 is expressed in a significant number of urothelial carcinomas (low grade) and this marker could be used in routine practice for early identification of patients at high risk of progression to advanced stage.